CY1116685T1 - Μεθοδος συζευξης βακτηριακων πολυσακχαριτων σε φερουσες πρωτεϊνες - Google Patents
Μεθοδος συζευξης βακτηριακων πολυσακχαριτων σε φερουσες πρωτεϊνεςInfo
- Publication number
- CY1116685T1 CY1116685T1 CY20151100798T CY151100798T CY1116685T1 CY 1116685 T1 CY1116685 T1 CY 1116685T1 CY 20151100798 T CY20151100798 T CY 20151100798T CY 151100798 T CY151100798 T CY 151100798T CY 1116685 T1 CY1116685 T1 CY 1116685T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bacterial
- polysaghcars
- ferrous
- proteins
- consumption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Μέθοδος σύζευξης βακτηριακών σακχαριτών που περιλαμβάνουν σακχαρίτες από Streptococcus pneumoniae και Haemophilus influenzae με αναγωγική αμίνωση παρέχεται στην παρούσα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1003922.0A GB201003922D0 (en) | 2010-03-09 | 2010-03-09 | Conjugation process |
EP11709065.4A EP2544708B1 (en) | 2010-03-09 | 2011-03-07 | Conjugation process of bacterial polysaccharides to carrier proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116685T1 true CY1116685T1 (el) | 2017-03-15 |
Family
ID=42136725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100798T CY1116685T1 (el) | 2010-03-09 | 2015-09-14 | Μεθοδος συζευξης βακτηριακων πολυσακχαριτων σε φερουσες πρωτεϊνες |
CY20171100888T CY1119244T1 (el) | 2010-03-09 | 2017-08-22 | Μεθοδος συζευξης βακτηριακων πολυσακxαριτων σε φερουσες πρωτεϊνες |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100888T CY1119244T1 (el) | 2010-03-09 | 2017-08-22 | Μεθοδος συζευξης βακτηριακων πολυσακxαριτων σε φερουσες πρωτεϊνες |
Country Status (26)
Country | Link |
---|---|
US (3) | US8753645B2 (el) |
EP (2) | EP2544708B1 (el) |
JP (1) | JP5698770B2 (el) |
KR (2) | KR20130038233A (el) |
CN (1) | CN102883745A (el) |
AU (1) | AU2011226160B2 (el) |
BR (1) | BR112012022358B1 (el) |
CA (1) | CA2791926C (el) |
CY (2) | CY1116685T1 (el) |
DK (2) | DK2544708T3 (el) |
EA (1) | EA023059B1 (el) |
ES (2) | ES2545221T3 (el) |
GB (1) | GB201003922D0 (el) |
HR (2) | HRP20150935T1 (el) |
HU (2) | HUE027621T2 (el) |
LT (1) | LT2815762T (el) |
ME (1) | ME02204B (el) |
MX (2) | MX2012010388A (el) |
PL (2) | PL2815762T3 (el) |
PT (2) | PT2815762T (el) |
RS (1) | RS54188B1 (el) |
SG (2) | SG183476A1 (el) |
SI (2) | SI2815762T1 (el) |
SM (1) | SMT201500211B (el) |
WO (1) | WO2011110531A2 (el) |
ZA (1) | ZA201206637B (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
BRPI0612669B8 (pt) | 2005-06-27 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, composição, e composição liofilizada |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
MX362802B (es) | 2010-09-10 | 2019-02-13 | Wyeth Llc Star | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis. |
GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
CA2865745C (en) | 2012-03-09 | 2018-01-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN104736180A (zh) * | 2012-05-22 | 2015-06-24 | 诺华股份有限公司 | 脑膜炎球菌血清组x偶联物 |
WO2014097099A2 (en) * | 2012-12-20 | 2014-06-26 | Pfizer Inc. | Glycoconjugation process |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
PL404247A1 (pl) | 2013-06-07 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
PL3096783T3 (pl) | 2014-01-21 | 2021-12-13 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
SG11201604728XA (en) | 2014-01-21 | 2016-08-30 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
KR102049825B1 (ko) * | 2014-01-21 | 2019-12-03 | 화이자 인코포레이티드 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체 |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
JP7164200B2 (ja) | 2016-03-31 | 2022-11-01 | ポゴナ, エルエルシー | サッカライド-ポリペプチドコンジュゲートの組成物およびその使用の方法 |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
WO2018126229A2 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
WO2018144438A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
PE20201338A1 (es) | 2017-12-06 | 2020-11-25 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos |
WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
BR112020026899A2 (pt) | 2018-07-04 | 2021-03-30 | Vaxcyte, Inc. | Melhorias em conjugados imunogênicos |
CN113453708A (zh) | 2018-12-19 | 2021-09-28 | 默沙东公司 | 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法 |
US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
NZ249704A (en) | 1992-02-11 | 1996-11-26 | Jackson H M Found Military Med | A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
DK0658118T3 (da) | 1992-08-31 | 2002-05-06 | Baxter Healthcare Sa | Vaccine mod Neisseria meningitidis, gruppe C |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
DE69431624T2 (de) | 1993-05-18 | 2003-07-10 | Univ Ohio State Res Found | Impfstoff gegen mittelohrentzündung |
ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
WO1996029094A1 (en) | 1995-03-22 | 1996-09-26 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
JP4012252B2 (ja) | 1996-06-18 | 2007-11-21 | アルザ コーポレイション | 薬剤の経皮放出又はサンプリングを高めるための装置 |
WO1998018930A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
CA2271167C (en) | 1996-12-20 | 2007-01-09 | Alza Corporation | Device and method for enhancing transdermal agent flux |
DK0959905T3 (da) | 1997-01-21 | 2010-04-06 | Sanofi Pasteur | Polysaccharid-peptid-konjugater |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
WO1998055606A2 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
CA2312900A1 (en) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
KR100704826B1 (ko) | 1998-08-19 | 2007-04-09 | 박스터 헬쓰케어 에스.에이. | N-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트 |
JP4689044B2 (ja) | 1998-12-21 | 2011-05-25 | メディミューン,インコーポレーテッド | ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片 |
EP1163000B1 (en) | 1999-03-19 | 2008-02-27 | GlaxoSmithKline Biologicals S.A. | Vaccine against antigens from bacteriae |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
KR20050086427A (ko) | 2002-11-07 | 2005-08-30 | 시너지 아메리카 인코포레이티드 | 폐렴균의 감염 치료 또는 예방용 조성물 및 방법 |
CN1798563A (zh) | 2003-05-15 | 2006-07-05 | 独立行政法人科学技术振兴机构 | 免疫刺激剂 |
US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
BRPI0413309B8 (pt) | 2003-08-06 | 2021-05-25 | The Government Of The Us Secretary Department Of Health And Human Services | método para a preparação de uma vacina conjugada de polissacarídeo-proteína |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
TWI445545B (zh) | 2005-04-08 | 2014-07-21 | Wyeth Corp | 多價肺炎球菌多醣-蛋白質共軛物組合物 |
US20070184072A1 (en) * | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
BRPI0612669B8 (pt) * | 2005-06-27 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, composição, e composição liofilizada |
US20090010959A1 (en) | 2005-12-22 | 2009-01-08 | Ralph Leon Biemans | Pneumococcal Polysaccharide Conjugate Vaccine |
CN105267974A (zh) | 2007-06-20 | 2016-01-27 | 辉瑞爱尔兰制药公司 | 用于缀合疫苗的经过修饰的多糖 |
BRPI0813307C1 (pt) | 2007-06-26 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, e, processo para fabricar a vacina |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
-
2010
- 2010-03-09 GB GBGB1003922.0A patent/GB201003922D0/en not_active Ceased
-
2011
- 2011-03-07 SG SG2012062741A patent/SG183476A1/en unknown
- 2011-03-07 PT PT141810754T patent/PT2815762T/pt unknown
- 2011-03-07 ES ES11709065.4T patent/ES2545221T3/es active Active
- 2011-03-07 LT LTEP14181075.4T patent/LT2815762T/lt unknown
- 2011-03-07 ES ES14181075.4T patent/ES2636940T3/es active Active
- 2011-03-07 MX MX2012010388A patent/MX2012010388A/es active IP Right Grant
- 2011-03-07 MX MX2014009548A patent/MX351345B/es unknown
- 2011-03-07 DK DK11709065.4T patent/DK2544708T3/en active
- 2011-03-07 AU AU2011226160A patent/AU2011226160B2/en not_active Ceased
- 2011-03-07 PL PL14181075T patent/PL2815762T3/pl unknown
- 2011-03-07 BR BR112012022358-5A patent/BR112012022358B1/pt active IP Right Grant
- 2011-03-07 EP EP11709065.4A patent/EP2544708B1/en active Active
- 2011-03-07 HU HUE11709065A patent/HUE027621T2/en unknown
- 2011-03-07 SI SI201131268T patent/SI2815762T1/sl unknown
- 2011-03-07 HU HUE14181075A patent/HUE035971T2/en unknown
- 2011-03-07 US US13/581,824 patent/US8753645B2/en active Active
- 2011-03-07 JP JP2012556477A patent/JP5698770B2/ja active Active
- 2011-03-07 ME MEP-2015-121A patent/ME02204B/me unknown
- 2011-03-07 RS RS20150552A patent/RS54188B1/en unknown
- 2011-03-07 KR KR1020127026281A patent/KR20130038233A/ko active Application Filing
- 2011-03-07 EA EA201290692A patent/EA023059B1/ru not_active IP Right Cessation
- 2011-03-07 PT PT117090654T patent/PT2544708E/pt unknown
- 2011-03-07 WO PCT/EP2011/053400 patent/WO2011110531A2/en active Application Filing
- 2011-03-07 CN CN2011800233222A patent/CN102883745A/zh active Pending
- 2011-03-07 DK DK14181075.4T patent/DK2815762T3/en active
- 2011-03-07 SG SG10201500413UA patent/SG10201500413UA/en unknown
- 2011-03-07 CA CA2791926A patent/CA2791926C/en active Active
- 2011-03-07 PL PL11709065T patent/PL2544708T3/pl unknown
- 2011-03-07 KR KR1020157036786A patent/KR20160005793A/ko not_active Application Discontinuation
- 2011-03-07 SI SI201130582T patent/SI2544708T1/sl unknown
- 2011-03-07 EP EP14181075.4A patent/EP2815762B1/en active Active
-
2012
- 2012-09-04 ZA ZA2012/06637A patent/ZA201206637B/en unknown
-
2014
- 2014-03-10 US US14/202,119 patent/US9265839B2/en active Active
- 2014-03-10 US US14/202,419 patent/US9265840B2/en active Active
-
2015
- 2015-09-07 HR HRP20150935TT patent/HRP20150935T1/hr unknown
- 2015-09-09 SM SM201500211T patent/SMT201500211B/xx unknown
- 2015-09-14 CY CY20151100798T patent/CY1116685T1/el unknown
-
2017
- 2017-07-28 HR HRP20171161TT patent/HRP20171161T1/hr unknown
- 2017-08-22 CY CY20171100888T patent/CY1119244T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119244T1 (el) | Μεθοδος συζευξης βακτηριακων πολυσακxαριτων σε φερουσες πρωτεϊνες | |
EP3517631C0 (en) | MUTANT MICROORGANISMS FOR THE SYNTHESIS OF PH-SENSITIVE MOLECULES AND ORGANIC ACIDS | |
BRPI0717341A2 (pt) | Método de produção de chapas elétricas não orientadas excelentes em propriedades magnéticas | |
BR112014002219A2 (pt) | conjugados anticorpo p97 e métodos de sua utilização | |
GB2453080B (en) | Efficient and accurate alignment of stereoscopic displays | |
EP2115492A4 (en) | DIRECT INVERSION BY TIME INTERVAL OF SEISMIC DATA | |
EP2131205A4 (en) | MAGNETIC SENSOR AND SENSITIVITY MEASUREMENT METHOD | |
DK2400298T3 (da) | Enkelt B-celle-dyrkningsfremgangsmåde og specifik antistoffremstilling | |
PL2332340T3 (pl) | Sposób przetwarzania informacji o paralaksie zawartej w sygnale | |
BRPI0916598A2 (pt) | métodos e composições para aumentar a produção de produtos em micro-organismos | |
GB2444375B (en) | Method and system to display well properties information | |
EP2696211A4 (en) | MONO-CHIP BRIDGE MAGNETIC FIELD SENSOR AND METHOD FOR PREPARING SAME | |
BRPI0906237A8 (pt) | manipulação de informações de sistema específico de células e tempo para entrega em utra evoluído | |
IN2012DN00939A (el) | ||
GB0910725D0 (en) | Mutant proteins and methods for producing them | |
BRPI0905620A2 (pt) | Transdutor magnético | |
GB2484176B (en) | Methods and systems for measuring NMR characteristics in production logging | |
BRPI0908183A2 (pt) | membro embalado e método de produção do mesmo | |
BRPI0815176A2 (pt) | Método e sensor para perceber moedas para avaliação | |
EP2576587A4 (en) | MUTANT NGAL PROTEINS AND USES THEREOF | |
EP2249731A4 (en) | MAGNETIC TARGET SYSTEM AND METHOD OF APPLICATION THEREFOR | |
HK1156056A1 (zh) | 經修飾的抗-肝素/ 複合物抗體以及 抗體標準 | |
BRPI0821150A2 (pt) | artigo do vestuário e método para sua fabricação | |
FI20096404A0 (fi) | Menetelmä ja järjestelmä tiedon siirtoon salattuna | |
HK1155074A1 (en) | Natural product inhibitors of 3dg 3- |